Overview

ALL Backbone in AYAs

Status:
NOT_YET_RECRUITING
Trial end date:
2035-07-31
Target enrollment:
Participant gender:
Summary
The goal of this research study is to evaluate a chemotherapy regiment for the treatment of newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs). The names of the study drugs involved in this study are: * blinatumomab (a type of immunotherapy drug) * cyclophosphamide (a type of chemotherapy drug) * cytarabine (a type of antineoplastic agent) * dexamethasone (a type of synthetic glucocorticoid) * doxorubicin (a type of antineoplastic agent) * etoposide (a type of antineoplastic agent) * mercaptopurine (a type of antineoplastic agent) * methotrexate (a type of chemotherapy drug) * pegaspargase (a type of antineoplastic agent) * vincristine (a type of antineoplastic agent)
Phase:
PHASE2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Treatments:
blinatumomab
Calcium Dobesilate
Cyclophosphamide
Cytarabine
Dexamethasone
Doxorubicin
Etoposide
etoposide phosphate
Mercaptopurine
Methotrexate
pegaspargase
Vincristine